The ability of immune cells-particularly CD8 + T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and ...

In a study published in Nature Aging on Nov. 26, a research team from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences revealed that aging specifically impairs ...

Study uncovers a pathogenic subset of memory T-cells that promote tissue inflammation and highlights a potential target for treating nasal polyps and other inflammatory airway diseases. Study: ...

IL-2 is clinically validated as an immunotherapeutic, but its use is limited by toxicity issues. AZD-6750 is an approach from Astrazeneca plc that applies cis-guiding to deliver a modified IL-2 mutein ...

Immunotherapy has been one of the most transformative treatments for cancer patients in recent decades, shifting the emphasis ...

Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial ...

Researchers at the Max Delbrück Center and the University of Oxford have found that a cellular housekeeping function called autophagy—by which cell components are broken down and recycled—plays a ...

At the AD/PD meeting held last month in Vienna, scientists implicated T lymphocytes—specifically, the cytotoxic, CD8-positive variety—in Alzheimer’s disease. While the modus operandi of these cells in ...

Tevogen Bio announced an agreement with CD 8 Technology Services to develop a turn-key facility aimed at enhancing its in-house capabilities for pre-clinical research and GMP cell therapy production.